Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2017, Article ID 1658473, 7 pages
https://doi.org/10.1155/2017/1658473
Case Report

SLE and Non-Hodgkin’s Lymphoma: A Case Series and Review of the Literature

1Department of Internal Medicine, Advocate Illinois Masonic Medical Center, 836 W. Wellington Avenue, Chicago, IL 60657, USA
2Department of Rheumatology, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA

Correspondence should be addressed to Abdul S. Mohammed; moc.liamg@namlasludbam

Received 9 December 2016; Accepted 16 March 2017; Published 27 March 2017

Academic Editor: Ruben Burgos-Vargas

Copyright © 2017 Prajwal Boddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Cao, H. Tong, G. Xu et al., “Systemic lupus erythematous and malignancy risk: a meta-analysis,” PLoS ONE, vol. 10, no. 4, Article ID e0122964, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Bernatsky, R. Ramsey-Goldman, J. Labrecque et al., “Cancer risk in systemic lupus: an updated international multi-centre cohort study,” Journal of Autoimmunity, vol. 42, pp. 130–135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Pettersson, E. Pukkala, L. Teppo, and C. Friman, “Increased risk of cancer in patients with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 51, no. 4, pp. 437–439, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Y. Kang, H. O. Kim, H. S. Yoon et al., “Incidence of cancer among female patients with systemic lupus erythematosus in Korea,” Clinical Rheumatology, vol. 29, no. 4, pp. 381–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. K. King and K. H. Costenbader, “Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL),” Clinical Rheumatology, vol. 26, no. 9, pp. 1491–1494, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Sweeney, S. Manzi, J. Janosky et al., “Risk of malignancy in women with systemic lupus erythematosus,” Journal of Rheumatology, vol. 22, no. 8, pp. 1478–1482, 1995. View at Google Scholar · View at Scopus
  7. S. Bernatsky, L. Joseph, J.-F. Boivin et al., “The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study,” Annals of the Rheumatic Diseases, vol. 67, no. 1, pp. 74–79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Tarr, B. Gyorfy, É. Szekanecz et al., “Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center,” Annals of the New York Academy of Sciences, vol. 1108, pp. 76–82, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Bernatsky, R. Ramsey-Goldman, and A. E. Clarke, “Malignancy in systemic lupus erythematosus: what have we learned?” Best Practice and Research: Clinical Rheumatology, vol. 23, no. 4, pp. 539–547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Löfström, C. Backlin, C. Sundström, A. Ekbom, and I. E. Lundberg, “A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study,” Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1627–1632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Sultan, Y. Ioannou, and D. A. Isenberg, “Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review,” Rheumatology, vol. 39, no. 10, pp. 1147–1152, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Abu-Shakra, D. D. Gladman, and M. B. Urowitz, “Malignancy in systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 39, no. 6, pp. 1050–1054, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Bernatsky, R. Ramsey-Goldman, R. Rajan et al., “Non-Hodgkin's lymphoma in systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1507–1509, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Bernatsky, J. F. Boivin, L. Joseph et al., “Race/ethnicity and cancer occurrence in systemic lupus erythematosus,” Arthritis Care and Research, vol. 53, no. 5, pp. 781–784, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. U. Hassan, S. Mushtaq, N. Mamoon, A. Hussain Asghar, and S. Ishtiaq, “Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1341–1347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Gillmore and W. Y. Sin, “Systemic lupus erythematosus mimicking lymphoma: the relevance of the clinical background in interpreting imaging studies,” BMJ Case Reports, 2014. View at Publisher · View at Google Scholar
  17. S. Bernatsky, R. Ramsey-Goldman, S. Lachance, C. A. Pineau, and A. E. Clarke, “Lymphoma in a patient with systemic lupus erythematosus,” Nature Clinical Practice Rheumatology, vol. 2, no. 10, pp. 570–574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. R. I. Fisher, “Overview of non-Hodgkin's lymphoma: biology, staging, and treatment,” Seminars in Oncology, vol. 30, no. 2, supplement 4, pp. 3–9, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Rossi, G. Catania, M. Truini, G. L. Ravetti, L. Grassia, and A. M. Marmont, “Patients with systemic lupus erythematosus (SLE) having developed malignant lymphomas. Complete remission of lymphoma following high-dose chemotherapy, but not of SLE,” Clinical and Experimental Rheumatology, vol. 29, no. 3, pp. 555–559, 2011. View at Google Scholar · View at Scopus
  20. J. R. Brown and A. T. Skarin, “Clinical mimics of lymphoma,” The Oncologist, vol. 9, no. 4, pp. 406–416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Bernatsky, R. Ramsey-Goldman, L. Joseph et al., “Lymphoma risk in systemic lupus: effects of disease activity versus treatment,” Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 138–142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. L. Browning, “B cells move to centre stage: novel opportunities for autoimmune disease treatment,” Nature Reviews Drug Discovery, vol. 5, no. 7, pp. 564–576, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. E. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardiman, Eds., Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2001.
  24. L. Pasqualucci, P. Neumeister, T. Goossens et al., “Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas,” Nature, vol. 412, no. 6844, pp. 341–346, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. F. N. Papavasiliou and D. G. Schatz, “Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity,” Cell, vol. 109, no. 2, supplement 1, pp. S35–S44, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Montesinos-Rongen, D. Van Roost, C. Schaller, O. D. Wiestler, and M. Deckert, “Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation,” Blood, vol. 103, no. 5, pp. 1869–1875, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Küppers, U. Klein, M.-L. Hansmann, and K. Rajewsky, “Cellular origin of human B-cell lymphomas,” New England Journal of Medicine, vol. 341, no. 20, pp. 1520–1529, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. James and J. M. Robertson, “Lupus and epstein-barr,” Current Opinion in Rheumatology, vol. 24, no. 4, pp. 383–388, 2012. View at Publisher · View at Google Scholar
  29. A. H. Draborg, K. Duus, and G. Houen, “Epstein-barr virus and systemic lupus erythematosus,” Clinical and Developmental Immunology, vol. 2012, Article ID 370516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Epeldegui, Y. P. Hung, A. McQuay, R. F. Ambinder, and O. Martínez-Maza, “Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations,” Molecular Immunology, vol. 44, no. 5, pp. 934–942, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Bailey, “Intracranial sarcomatous tumors of leptomeningeal origin,” Archives of Surgery, vol. 18, no. 4, pp. 1359–1402, 1929. View at Publisher · View at Google Scholar
  32. T. N. Shenkier, J.-Y. Blay, B. P. O'Neill et al., “Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2233–2239, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. F. H. Hochberg and D. C. Miller, “Primary central nervous system lymphoma,” Journal of Neurosurgery, vol. 68, no. 6, pp. 835–853, 1988. View at Publisher · View at Google Scholar · View at Scopus
  34. C. N. Pisoni, A. R. Grinberg, J. L. Plana, R. D. Freue, J. A. Manni, and L. Paz, “Primary central nervous system lymphoma in a patient with systemic lupus erythematosus,” Medicina, vol. 63, no. 3, pp. 221–223, 2003. View at Google Scholar · View at Scopus
  35. B. Svobodova, Z. Hruskova, R. Rysava, and V. Tesar, “Brain diffuse large B-cell lymphoma in a systemic lupus erythematosus patient treated with immunosuppressive agents including mycophenolate mofetil,” Lupus, vol. 20, no. 13, pp. 1452–1454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. H. H. L. Tsang, N. J. Trendell-Smith, A. K. P. Wu, and M. Y. Mok, “Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus,” Lupus, vol. 19, no. 3, pp. 330–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. P. F. Finelli, K. Naik, J. A. DiGiuseppe, and A. Prasad, “Primary lymphoma of CNS, mycophenolate mofetil and lupus,” Lupus, vol. 15, no. 12, pp. 886–888, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Dasgupta, A. C. Gelber, F. Racke, and D. M. Fine, “Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis,” Lupus, vol. 14, no. 11, pp. 910–913, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. M.-G. Kim, S. Y. Park, E. J. Kim et al., “Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment,” Acta Haematologica, vol. 125, no. 3, pp. 121–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Meng, S. He, Q. Liu, D. Xu, T. Zhang, and Z. Chen, “High prevalence of hepatitis B virus infection in primary central nervous system lymphoma,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 6, pp. 9937–9942, 2015. View at Google Scholar · View at Scopus
  41. P. M. Bracci, “Obesity and hepatitis B infection and risk of primary CNS lymphoma,” Blood, vol. 122, no. 21, 2013. View at Google Scholar
  42. G. Ruiz-Irastorza, A. Ugarte, M. V. Egurbide et al., “Antimalarials may influence the risk of malignancy in systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 66, no. 6, pp. 815–817, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. R. F. Ambinder, “Gammaherpesviruses and “hit-and-run” oncogenesis,” American Journal of Pathology, vol. 156, no. 1, pp. 1–3, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. P. L. Zinzani, A. Broccoli, V. Stefoni et al., “Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients,” Cancer, vol. 116, no. 24, pp. 5667–5675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Y. Lin, H. Y. Zhang, Y. Huang et al., “Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China—a multi-center randomized trial,” Ai Zheng, vol. 24, no. 12, pp. 1421–1426, 2005. View at Google Scholar
  46. M. Holdhoff, P. Ambady, A. Abdelaziz et al., “High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma,” Neurology, vol. 83, no. 3, pp. 235–239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Alchi, D. Jayne, M. Labopin et al., “Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry,” Lupus, vol. 22, no. 3, pp. 245–253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Klyuchnikov, U. Bacher, T. Kroll et al., “Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?” Bone Marrow Transplantation, vol. 49, no. 1, pp. 1–7, 2014. View at Publisher · View at Google Scholar · View at Scopus